Key Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors Pleased to announce a new report on "Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors" into its market report catalogue for reselling.
Spread the Word
Listed Under

Market Research Reports


Navi Mumbai - Maharashtra - India

Feb. 18, 2013 - PRLog -- Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors


New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

Key Points Discussed in the Report

• Drugs in the pipeline
PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)
Dual PI3K inhibitor – Onconova/SymBio, Curis (CRIS)
BTK-inhibitors – Safety and clinical efficacy set it apart – Pharmacyclics (PCYC), Celgene (CELG)
• M&A in Kinase Inhibitors in the last 5 years
• Related Milestones/catalysts in 2013-14
• Combination Studies – PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
• Ongoing Clinical Trials of Companies Covered
• Detailed reports on
 SymBio pharma ( (4582, ¥488)
 Curis ( (CRIS, $2.99)
 Gilead ( (GILD, $40.36)
 Pharmacyclics ( (PCYC, $69.28) –
Infinity pharma (INFI, $35.02)

Request for Sample pages -
Table of Contents
Executive Summary
Drugs in the Pipeline
Phosphoinositide 3-Kinases (PI3Ks) inhibitors
Scientific Rationale
Dual inhibitors
Bruton’s Tyrosin Kinase (BTK) Inhibitors
Scientific Rationale

BTK inhibitors – Pipeline
M&A to Follow – Kinase inhibitors have attracted partnering deals at a premium
Kinase Inhibitor: Select M&A / Deals

Upcoming Milestones Related in 2013-14

Combination Studies – PI3K, BTK + Rituxan/ Bendamustine
Idelalisib (GS-1101) – Clinical Data
Rigosertib – Clinical Data
Other PI3K or Dual Inhibitors – Clinical Data
Combination Studies of PI3K and BTK Inhibitors

Ongoing Trials of PI3K and BTK Compounds

Company Analysis
Curis (CRIS) – Time to Assess Value Beyond Erivedge!
Gilead –
Infinity Pharma

For more information kindly visit :          


Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:
Follow us on Linkedin :
Our Blog :
Source:Bharat Book Bureau
Posted By:*** Email Verified
Phone:00 91 22 27810772 27810773
Tags:Pharma, Cancer, Medical, Drugs, Market Research Reports
Industry:Health, Medical
Location:Navi Mumbai - Maharashtra - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Bharat Book PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share